Hair Loss
Evidence-Based Hair Loss Solutions: Prescription, Compounded & OTC Treatments
Targeted approaches for every stage of androgenetic alopecia
Hair loss (androgenetic alopecia) affects over 80 million Americans, primarily driven by genetic sensitivity to DHT. Modern science provides targeted solutions at every stage of progression. This guide compares FDA-approved drugs, compounded topicals, and OTC/device-based options based on proven efficacy and safety profiles.
Core Mechanism: How DHT Triggers Hair Loss
Genetic sensitivity determines progression speed. Early intervention is key to preserving existing follicles and slowing miniaturization.
Prescription Pharmaceuticals (Highest Efficacy)
1. 5a-Reductase Inhibitors
| Medication | Formulation | Key Benefit | Best For |
|---|---|---|---|
| Finasteride | Oral tablet (1mg daily) | Reduces scalp DHT by 60–70% | Men with vertex/crown thinning |
| Dutasteride | Oral capsule (0.5mg daily) | Blocks 90%+ DHT (all 3 isoforms) | Men with aggressive loss |
| Propecia® | Branded finasteride | Same efficacy as generic | Patients preferring brand assurance |
Prescription Required: Not for premenopausal women. Reported side effects <2% (reversible upon discontinuation).
2. Anti-Androgens (Women-Specific)
- Spironolactone: Oral anti-androgen (50–200mg/day)
- Topical Finasteride: Compounded formulas minimize systemic absorption
- Oral Minoxidil: Low-dose (0.25–1.25mg) enhances growth phase
Compounded Formulations (Precision Topicals)
Custom solutions that deliver actives directly to follicles while minimizing systemic exposure.
| Product | Active Ingredients | Clinical Advantage |
|---|---|---|
| Mens Hair TriGro | Minoxidil 5% + Finasteride 0.1% + Tretinoin 0.01% | Combats DHT + enhances absorption |
| Womens Hair TriGro Ageless | Minoxidil 2% + Spironolactone 1% + Biotin 0.5% | Anti-androgen + follicle nutrition |
| Womens Hair TriGro Vibrant | Minoxidil 5% + Finasteride 0.025% + Melatonin 0.1% | Nighttime growth stimulation |
2024 JAMA Study: Topical finasteride reduced serum DHT by only 24% vs. 70% with oral therapy.
OTC & Device Solutions
Topical Agents
| Product | Key Actives | Mechanism |
|---|---|---|
| Minoxidil | 5% (men), 2–5% (women) | Vasodilator ? ? follicular nutrients |
| Hair Growth for Men | Caffeine + Adenosine | Blocks DHT binding + reduces inflammation |
| Hair Growth for Women | Capixyl™ + Redensyl | Stem cell activation + antioxidant support |
Devices
| Product | Technology | Clinical Protocol |
|---|---|---|
| Laser Hair Growth Comb | Low-level laser (650nm) | 10min, 3x/week (FDA-cleared) |
| Minoxidil Applicator Comb | Precision nozzle | Targets thinning zones |
Treatment Roadmap by Stage
Early Stage
- Men: Hair Growth for Men
- Women: Hair Growth for Women
- Device: Laser comb 3x/week
Progressive
- Men: Oral finasteride or Compounded TriGro
- Women 45+: TriGro Ageless
- Women -45: TriGro Vibrant
Advanced
- Men: TriGro Men + Hair Growth for Men + Lazer Comb
- Women 45+: TriGro Ageless + Hair Growth for Women + Lazer Comb
- Women -45: TriGro Vibrant + Hair Growth for Women + Lazer Comb
Critical Safety Protocols
- Finasteride: men only.
- TriGro Rx: men and women
- Natural Supplements: Men and women hair growth.
- Laser Therapy: Stick to FDA-cleared devices.
Realistic Treatment Timeline
- + Months 1–3: Reduced shedding
- + Months 4–6: Vellus hair emergence
- + Months 8–12: Visible density improvement
- - Full results require 18–24 months
Tip: Switch protocols at 6 months if no reduction in shedding is observed.
When to Consult a Specialist
Seek Doctor evaluation for:
- Sudden patchy loss (possible alopecia areata)
- Scalp inflammation or pain (possible scarring alopecia)
- Treatment resistance after 12 consistent months
- Women with PCOS symptoms (acne + hair loss)
